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The circulating form of atria1 natriuretic factor is a 28-residue peptide containing a 17-residue disulphide-linked ring. 
It has important actions on the kidney, largely on its haemodynamics, and at other sites including the adrenal cortex 
and CNS. It has a short half-life in vivo and is rapidly inactivated when incubated with kidney microvillar membranes. 
Of the battery of peptidases present in that membrane, only one, endopeptidase-24.11, is responsible for initiating the 
attack, and this commences with hydrolysis of the Cys’-PheS bond within the ring. Hydrolysis at this and other points 
has been shown to inactivate the peptide and this information has pointed the way to the synthesis of resistant analogues. 
Atria1 natriuretic peptide; Membrane peptidase; Neuropeptide; Endopeptidase-24.11 
1. DISCOVERY OF ATRIAL NATRIURETIC 
FACTOR 
Atria1 natriuretic factor (ANF) comprises a 
family of peptides with powerful natriuretic, 
diuretic and hypotensive activities which are pre- 
sent in storage granules of atrial muscle. The ex- 
istence of these granules and their resemblance to 
secretory granules of other cells were reported 
more than 20 years ago [1,2] but the chemical 
nature of their contents was a mystery until quite 
recently. The first clues were the observation that 
the number of granules, assessed microscopically, 
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could be affected by changes in the intake of water 
and sodium [3] and that injections of extracts of 
atria or granules promoted diuresis and natriuresis 
[4] and by 1983 it was becoming clear that these ac- 
tivities resided in a group of related peptides (for 
review and nomenclature see [S]). Several low-M, 
peptides have been isolated from rat atria, e.g. 
atriopeptins I, II and III and cu-rat atria1 natriuretic 
peptide (cu-rANP), all of which possess a 
disulphide-linked loop of 17 amino acid residues, 
with short N- and C-terminal extensions. 
However, the major circulating form of ANF in 
the rat appears to be the 28-residue peptide [6,7] 
which is derived from a high-M,, 152-residue 
precursor, rat pre-pro ANP (see [5]). Human atria 
also release a 28-amino acid peptide @-human 
atrial natriuretic peptide, a-hANP; [8]; fig.1) 
which differs from a-rANP by only one residue, 
Met” for Ilei* [9]. 
2. REGULATION OF RELEASE OF ANP 
Several factors have been found to stimulate 
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release of ANP. The infusion of isotonic saline in- 
to the rat, corresponding to a 30% expansion of 
volume, gave a 6lfold increase in plasma ANF-like 
material [lo], the major component of the im- 
munoreactive material being a-rANP( l-28) [ 111. 
Administration of pharmacological doses of 
[Arg’]vasopressin also stimulated release of ANP 
[12] and a negative feedback loop has been 
postulated whereby [Arg’]vasopressin stimulates 
ANP release, which in turn suppresses 
[Arga]vasopressin secretion. 
3. BIOLOGICAL EFFECTS AND 
MECHANISM OF ACTION OF ANP 
Injection of atrial extract into rats causes 
natriuresis, diuresis and chloruresis [4]. The 
mechanism of the natriuretic effect of ANP has 
been the subject of considerable controversy but 
the findings obtained to date strongly support the 
theory that the ANP-induced natriuresis is largely 
due to its effects on renal haemodynamics, par- 
ticularly the increase in glomerular filtration rate 
[13,14]. It seems that this is brought about by 
vasodilation of afferent arterioles and vasocon- 
striction of efferent vessels. Micropuncture studies 
have indicated that the natriuretic effect of ANP 
may be due, in part, to an inhibition of sodium 
transport along the collecting tubules and col- 
lecting ducts, but without affecting this process in 
proximal or distal tubules. It has been shown that 
a-rANP(Arg3-Tyr28) inhibits angiotensin II- and 
ACTH-stimulated aldosterone secretion in rat 
adrenal glomerulosa cells in vivo and in vitro 
[ 15,161. The primary site of action of aldosterone 
is the cortical collecting tubule, where it slowly 
causes a decrease in sodium and an increase in 
potassium excretion [17]. However, since the 
ANP-induced natriuresis occurs within minutes 
[ 181, this rapid action cannot be related to reduced 
aldosterone output. 
Apart from the renal effects mentioned above, 
ANP also reduces cardiac output, probably by in- 
directly reducing stroke volume and heart contrac- 
tility [19], and causes relaxation of vascular 
smooth muscle [20,21] both of which could lead to 
the fall in blood pressure which is observed after 
ANP administration [181. 
Some of the effects of ANP may be centrally 
mediated since ANP immunoreactivity has been 
found in various areas of the brain known to be in- 
volved in the regulation of fluid and electrolyte 
balance and cardiovascular homeostasis [22]. 
Several areas of the brain contain receptors for 
ANP, for example the subfornical organ and area 
postrema [23,24] and choroid plexus [25] and a- 
hANP has been demonstrated [26] in human 
cerebrospinal fluid. Furthermore, when a-rANP 
was injected intraventricularly it inhibited produc- 
tion of cerebrospinal fluid [27], suggesting that 
ANP is relevant to CNS water regulation under 
normal conditions and perhaps in the pathology of 
cerebral edema and hydrocephalus. 
4. ANP STRUCTURE-ACTIVITY 
RELATIONSHIPS 
The integrity of the disulphide bridge has been 
shown to be essential for activity. Reduction and 
carboxymethylation abolished natriuretic and 
diuretic actions [28] and no inhibitory effect on 
aldosterone secretion from adrenal glomerulosa 
cells was observed after performic acid oxidation 
[29]. The linear fragment cu-rANP(Phe8-Arg27) 
had very little activity compared with a- 
rANP(Ser5-Arg27) [30] suggesting that hydrolysis 
of a peptide bond within the disulphide-linked 
loop would be sufficient to inactivate. Also, 
removal of the C-terminal tripeptide (Phe-Arg- 
Tyr) from cu-rANP(Arg4-Tyr2*) markedly de- 
creased, but did not abolish, natriuretic and 
vasorelaxant actions [3 11. 
5. INACTIVATION OF ANP BY TISSUES 
Several groups have demonstrated a very rapid 
turnover of a-rANP in vivo, in which the kidneys 
play a major part [32-341, but the mode of attack 
and the nature of the peptidases involved has only 
recently become clear. An early report described 
an atrial enzyme activity which converted atriopep- 
tin II [a-rANP(Ser5-Arg27)] to atriopeptin I [cy- 
rANP(Ser’-SerZ5)] by removal of the C-terminal 
dipeptide Phe-Arg [35]. Later it was observed that 
atriopeptin III [cu-rANP(Ser5-Tyr2*)] was de- 
graded by rabbit brush border membranes with 
hydrolysis at the Ser’-Ser6, Cys7-Phe’ and 
Ser25-Phe26 peptide bonds [36]. More detailed 
studies on the mode of attack by renal brush 
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border membranes have now led to the identity of dictate a different fate whereby the principal at- 
the peptidase responsible. tack is dependent on E-24.11. 
5.1. Kidney microvillar peptidases 
No membrane is richer in peptidases than that of 
the renal brush border; they are listed and their 
specificity summarized in table 1. Many of the 
same enzymes are expressed on the surfaces of a 
variety of other cell types, not only in brush 
borders such as those of the intestine, placenta and 
choroid plexus, but on many other cells, including 
those of the nervous system (for recent review see 
[37]). The activity of this battery of peptidases, all 
active at neutral pH, is directed towards simple 
peptides, native proteins being wholly resistant o 
attack. Thus, substance P, bradykinin, angioten- 
sins I, II and III, and insulin B chain, are all rapid- 
ly degraded in vitro by pig kidney microvillar 
membranes. In the same conditions, oxytocin was 
degraded an order of magnitude more slowly while 
vasopressin and insulin remained intact [39]. LY- 
hANP is one of the group of very susceptible pep- 
tides, being attacked at rates comparable to 
angiotensins II and III [40]. 
Microvillar membrane preparations provide a 
valuable model system for predicting the likely 
metabolism of a peptide in vivo, since most, 
though possibly not quite all, of the known cell 
surface peptidases are represented in high concen- 
trations on this membrane. If conditions are 
selected to reveal the initial attack on a susceptible 
peptide, the products analysed and collected so 
that the bonds hydrolysed are defined, it is possible 
to predict the probable identity of the peptidases 
responsible. Fortunately, there are a number of 
specific inhibitors of the key peptidases (table 1) 
which can serve to confirm the identity as, too, can 
parallel experiments with isolated enzymes. This 
approach has shown that E-24.11 initiates the at- 
tack on bradykinin, substance P, angiotensins I, 
II, III, oxytocin and insulin B chain [39]. In some 
respects this was a surprising conclusion: peptidyl 
dipeptidase A (angiotensin converting enzyme) 
converts angiotensin I to II and inactivates 
bradykinin by removal of the C-terminal dipep- 
tides, His-Leu and Phe-Arg, respectively. While 
this is a physiologically important process in the 
capillaries of the lung (where peptidyl dipeptidase 
A but no E-24.11 is present; see [37]), the relative 
activities of the two peptidases in kidney microvilli 
With this background in mind and because the 
kidney is an important target organ for ANP, we 
have used the same approach to investigate the 
metabolism of this peptide [40]. In short incuba- 
tions of cr-hANP with pig E-24.11, the main pro- 
duct was a peptide with the same amino acid 
composition, but with a shorter retention time on 
HPLC. It was designated u-hANP’ and attributed 
to the hydrolysis of a single peptide bond within 
the S-Z&bridged 17-residue ring. When the diges- 
tion was allowed to run to completion, cu-hANP’ 
was further degraded and 9 peptides could be 
resolved on HPLC. Amino acid analysis of the 
four main peptide products indicated attacks at 
three points within the ring and one in the tail 
(solid arrows, fig. 1). In contrast, incubation of a- 
hANP with peptidyl dipeptidase A revealed no 
evidence of any fragments even after 24 h. With 
microvillar membranes incubated for 15 min the 
main product (22% yield), was LY-hANP’ , together 
with the C-terminal fragments (Phe-Arg-Tyr and 
free phenylalanine, 9% yield) and traces of other 
fragments from hydrolysis within the ring. Of the 
inhibitors, only phosphoramidon had a clear-cut 
effect, suppressing the yield of the fragments by 
SO-100% (fig.2). The formation of identical pep- 
tide products by the membranes and purified 
E-24.11, and the inhibitory effect of phosphor- 
amidon, confirm that the attack on cu-hANP is in- 
itiated by E-24.11 in this membrane. The identity 
of the bond initially hydrolysed to generate LY- 
hANP’ became clear when the products formed by 
pig E-24.11 on cu-rANP (which differs only in the 
substitution of Met” by Ile12) were analysed by se- 
quencing (kindly performed by Merrell Dow 
Research Institute). Two peptide sequences were 
revealed, a-rANP(Ser’-Cys7) and CY- 
rANP(Phe’-Tyr2’), thus showing that the first at- 
tack was at the Cys7-Phe’ bond. This point of 
hydrolysis has also been shown for ‘rat E-24.1 1 
[41]. Two other groups had reported hydrolysis of 
the same bond after incubation of cu-rANP with 
rabbit [36] or rat [42] brush border membranes, 
but in neither case was the identity of the peptidase 
established. Later, it was suggested that the rabbit 
enzyme might be E-24.11 [43] and its identity was 
firmly established in the case.of the rat [44]. 
Rat kidney microvilli contain endopeptidase-2, 
3 
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Table 1 
Peptidases o far identified in kidney microvilli 
Class Enzyme Active 
site 
Specificity Specific 
inhibitor 
Endopeptidases 
Aminopeptidases 
Carboxypeptidases 
Dipeptidyl peptidase 
Peptidyl dipeptidase 
Dipeptidase 
Transferase 
endopeptidase-24.11 
(EC 3.4.24.11, ? all species) 
endopeptidase-2 (rat kidney) 
meprin (mouse kidney) 
aminopeptidase N
(EC 3.4.11.2) 
aminopeptidase A
(EC 3.4.11.7) 
aminopeptidase W 
(EC 3.4.11.-) 
aminopeptidase P 
(EC 3.4.11.9) 
carboxypeptidase P 
(EC 3.4.17. -) 
carboxypeptidase M
(EC 3.4.17. -) 
dipeptidyl peptidase IV 
(EC 3.4.14.5) 
peptidyl dipeptidase A (ACE) 
(EC 3.4.15.1) 
microsomal dipeptidase 
(EC 3.4.13.11) 
y-glutamyl transferase 
(EC 2.3.2.2) 
Zn’+ 
Zn2+ 
Zn2+ 
Zn2+ 
Ca2+ 
Zn2+ 
? 
Zn2+ 
? 
serine 
Zn2+ 
Zn2+ 
- 
-cl&-O- 
(hydrophobic) 
& 
(hydrophobic) 
X-o%-&G 
(hydrophobic) 
(many) 
(C&r/Asp) 
(Trp) 
(Pro) 
(Pro,Ala,Gly) 
(Lys,Arg) 
(Pro,Ala) 
(nonspecific) 
& 
(nonspecific) 
phosphoramidon 
_ 
- 
amastatin 
amastatin 
amastatin 
_ 
- 
GEMSA 
Dip-F 
captopril 
cilastatin 
AT-125 
The data refer to pig except where otherwise stated. For reviews see [37,38]. GEMSA, guanidinoethylmercaptosuccinic 
acid; Dip-F, diisopropylfluorophosphate; AT-125, L-(S,5-5’)~amino-3-chloro-4,5-dihydro-5- isoxazoleacetic acid 
in addition to E-24.1 1 [45,46], and this raises the 
possibility that membranes from this species might 
metabolise ANP differently from those of pig, rab- 
4 
bit or human in which only E-24.11 is to be found. 
In fact the pattern of products released by brief ex- 
posure of a-hANP to rat microvillar membranes is 
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Fig. 1. Sequence of cu-hANP and points of hydrolysis by 
E-24.11. This human sequence differs from that of the rat (cu- 
rANP) in containing Met” in place of Ile”. The solid arrows 
show the main points of hydrolyses which we reported [40] and 
the open arrows indicate bonds cleaved by E-24.1 1 purified 
from human kidney [48]. The initial attack takes place at 
Cys’-Phes. 
indistinguishable from that observed with pig 
membranes and the hydrolysis was inhibited by 
phosphoramidon. Purified endopeptidase-2 hy- 
drolysed a-hANP very slowly (being incomplete 
after incubation for 6 h with l&l ng enzyme and 
5 nmol peptide) and the products differed from 
those observed with rat or pig microvillar mem- 
branes [47]. Endopeptidase-2 therefore appears to 
play little or no role in the metabolism of ANP, in 
agreement with the observation that the activity in 
rat kidney membranes responsible for the 
hydrolysis of cu-rANP at the Cys’-Phe’ bond is 
E-24.11 [44]. Another recent study [48] has used 
E-24.11 purified from human kidneys. Seven sites 
of attack were noted: Arg4-Se?, Cys’-Phe’, 
Arg”-Met”, Arg’4-Ile’S, Gly16-Ala’7, Gly*‘-Leu*’ 
and Ser25-Phe26 (open arrows, fig. 1). Of these, the 
cleavage of an Arg-Ser bond is atypical for an en- 
zyme which normally attacks bonds involving the 
amino group of hydrophobic residues. Yet the ef- 
fect of phosphoramidon on suppressing hydrolysis 
Ihe-Ely-Gl)-lrg-MbArp-Arg 
Fig.2. Effect of peptidase inhibitors on the formation of the 
main products when cr-hANP was incubated with pig 
microvillar membranes. The bars show the yield of each 
product. Solid bar, no inhibitors; cross-hatched, 1 PM 
phosphoramidon (P); stippled, 1 PM captopril (C); horizontal 
hatched, 1 PM amastatin (A). Data redrawn from [40]. All bars 
are plotted on the same scale, the yield of the main product, a- 
hANP’, being 1.1 nmol, corresponding to 22% hydrolysis at 
the Cys’-Phes bond. 
at this and other sites is consistent with this attack 
being attributable to E-24.11 and not to a minor 
contaminating activity. The initial point of 
hydrolysis at Cys’-Phe’ was again confirmed. 
5.2. Effect of the E-24.11 attack on the biological 
activity of cw-hANP 
The degradation of (Y-hANP by the brush border 
peptidases resembled that of substance P, 
bradykinin, the angiotensins and oxytocin in being 
predominantly initiated by E-24.11. The points of 
attack observed seem likely to inactivate ANP: the 
removal of the C-terminal tripeptide greatly 
reduces activity [31] and, since the integrity of the 
disulphide bridge is essential 128-301, it was 
predictable that hydrolysis of peptide bonds within 
the loop would also inactivate. Recently it has been 
confirmed that ring-opened cu-rANP(Ser’-Tyr*‘), 
generated by incubation with E-24.11, had approx. 
2% of the vasorelaxant activity of the parent pep- 
tide [49] and was at least lo-times less active than 
the parent peptide in causing hypotension, 
natriuresis and diuresis in spontaneously hyperten- 
sive rats [50]. The ring-opened metabolite of (Y- 
rANP(Ser’-Ser*‘) which also lacks the C-terminal 
tripeptide Phe-Arg-Tyr, was essentially inactive. It 
seems likely therefore that passage of ANP 
through the proximal renal tubule in vivo will suf- 
fice to inactivate the peptide. In assessing the 
physiological significance of these findings it 
should be recalled that the renal receptors for ANP 
and sites of action on Na+ transport are reported 
to be in the collecting ducts and tubules [51-541 
and would be physiologically relevant only if ac- 
cessible to ANP at the basolateral surface, since 
ANP will be cleared from the luminal fluid. ANP 
has other postulated sites of action, e.g. in renal 
glomerular membranes [25] where ANP may in- 
duce an increase in glomerular filtration rate [18], 
in the adrenal cortex causing inhibition of the 
release of aldosterone from the glomerulosa cells 
[ 151 as well as in the vascular smooth muscle where 
it is a vasorelaxant [20,21] and in the brain [23,24]. 
Since E-24.1 1 has a widespread distribution on 
plasma membranes in many tissues and organs 
[55-591 the inactivation of ‘ANP by E-24.11 may 
well occur at other sites in addition to the kidney. 
It is particularly interesting that in the adrenal cor- 
tex, endopeptidase-24.11 is discretely localized in 
the glomerulosa cells [37] where it may serve to in- 
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activate ANP and other peptide signals such as 
angiotensins II and III. 
5.3. Possible clinical importance 
a-hANP has been found to have therapeutic ac- 
tions in patients with essential hypertension and 
congestive heart failure [60] indicating the poten- 
tial of CZ-hANP as a new drug for such disorders. 
Much research is now being directed towards the 
synthesis of longer lasting, more potent analogues 
of this naturally occurring peptide. An analogue of 
cu-rANP(Cys7-Tyr”), lacking the six, N-terminal, 
(‘head’) amino acid residues, with 3-mercaptopro- 
pionic acid replacing Cys7, has been shown to have 
several-fold higher natriuretic and diuretic ac- 
tivities than cw-rANP(Arg3-Tyr’*) [61]. The resul- 
tant des-amino analogue would be resistant to 
attack by E-24.11 at Cys7-Phe* (its specificity re- 
quires as a minimum the binding at Si and SZ sites) 
and also to aminopeptidase attack. This resistance 
to enzymic degradation would suffice to explain 
the high potency of the analogue. 
Recently two atria1 natriuretic peptides have 
been identified in human coronary sinus plasma 
[62]. The amino acid sequence of one of the pep- 
tides indicated that it was identical with a-hANP. 
However, the amino acid sequence of the second 
peptide was consistent with cY-hANP(Ser’-Cys7) 
linked to cr-hANP(Phe*-Tyr2*) by the disulphide 
bond, which is now known to be the structure of 
cu-hANP ’ . The molar ratio of the peptides was 
10: 3, respectively. E-24.11 has been detected in 
heart tissue albeit in very low quantities [56], and 
we have shown that it hydrolyses the Cys7-Phe* 
bond of a-hANP, but its role in generating this 
derivative in the coronary sinus in vivo has yet to 
be established. 
6. WHAT IS THE PHYSIOLOGICAL ROLE OF 
THE RENAL BRUSH BORDER 
PEPTIDASES? 
It will be apparent from what has been said that 
the powerful hydrolytic activity of the microvillar 
peptidases, especially E-24.11, can, in vitro, rapid- 
ly degrade many regulatory peptides, including 
ANP. Micropuncture and microperfusion studies 
have shown that the passage of injected labelled 
peptides (e.g. bradykinin, angiotensins I, II, 
though not oxytocin) through the proximal tubule 
6 
is associated with their degradation (63-651, while 
injection of bradykinin into the distal tubule leads 
to complete recovery in the urine [63]. What is 
more difficult to comprehend is why such 
mechanisms exist to clear the glomerular filtrate of 
these peptides. Failure to do so would, in the 
absence of endocytic mechanisms for peptides (as 
distinct from proteins, e.g. insulin [66]), lead to 
their passage into the urine after some degree of 
concentration. The nutritional losses would appear 
to be trivial, amounting in the human to only a few 
milligrams of peptide. In regard to their biological 
actions the peptides will, in most cases, have been 
sequestered from their target organs, so that the 
choice of degradation versus excretion would not 
affect their biological turnover rate. There remains 
a possibility (one that we have argued before 
[37,67]) that the brush border peptidases exert a 
protective role by preventing certain peptides from 
reaching the distal part of the urinary system. ANP 
may be such a peptide. The concentrating power of 
the nephron would generate pharmacological 
rather than physiological concentrations of ANP, 
if not degraded in the proximal tubule. It has been 
shown that intraluminal injection of high concen- 
trations of bradykinin (50 x physiological) into 
the late proximal tubule caused increased 22Na ex- 
cretion [68]. It may be that this peptide and ANP 
in abnormally high intraluminal concentrations 
could gain access to receptors on the contraluminal 
surfaces to produce this response. Blockade of 
E-24.11 by intravenously infused phosphoramidon 
into anaesthesised rats has been reported to cause 
natriuresis and diuresis [69]. We have, in 
preliminary experiments, confirmed this effect of 
phosphoramidon on renal function, but unlike the 
first report, which suggested that it resulted from 
the protection of kinins from inactivation, we 
would surmise that there is a strong argument for 
the involvement of ANP. 
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